highlights in gynecological cancer€¦ · italfarmaco msd pharmamar roche principal invastigator:...
TRANSCRIPT
![Page 1: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/1.jpg)
QuickTime™ e undecompressore
sono necessari per visualizzare quest'immagine.
DANIELA SAMBATARO UOC Oncologia Medica
ARNAS GARIBALDI Catania
HIGHLIGHTS IN GYNECOLOGICAL CANCER
![Page 2: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/2.jpg)
DISCLOSURES
Tesaro
Astra Zeneca
Teva
Italfarmaco
MSD
Pharmamar
Roche
Principal invastigator: ATHENA, FIRST
![Page 3: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/3.jpg)
OBIETTIVO PRIMARIO:
FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI
> 70 anni GVS (GERIATRIC VULNERABILITY SCORE –GINECO-) ≥ 3
OBIETTIVI SECONDARI: safety, PFS, OS, QoL, fattibilità interval debulking e
terapia adiuvante post chirurgica, geriatric covariates e aging biomarker
![Page 4: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/4.jpg)
EWOC-1 design<br /> 2- Patient randomization
Presented By Claire Falandry at 2019 ASCO Annual Meeting
![Page 5: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/5.jpg)
EWOC-1 primary endpoint
![Page 6: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/6.jpg)
EWOC-1 toxicity
Presented By Claire Falandry at 2019 ASCO Annual Meeting
![Page 7: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/7.jpg)
EWOC-1 Progression-free survival
Presented By Claire Falandry at 2019 ASCO Annual Meeting
![Page 8: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/8.jpg)
EWOC-1 Overall survival
Presented By Claire Falandry at 2019 ASCO Annual Meeting
![Page 9: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/9.jpg)
The carboplatin single agent arm is also worse <br />even for the most vulnerable patients (GVS 4 & 5)
Presented By Claire Falandry at 2019 ASCO Annual Meeting
![Page 10: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/10.jpg)
EWOC-1
ANCHE NELLE PAZIENTI ANZIANE FRAGILI DOVREBBE ESSERE
EFFETTUATO UN REGIME CON CARBOPLATINO/PACLITAXEL
![Page 11: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/11.jpg)
CARCINOSARCOMA: BACKGROUND
• Rara e aggressiva
• Verosimile origine monoclonale
• Carcinosarcoma ovarico poco studiato
schema n ORR mPFS (mesi) mOS (mesi)
GOG 161 Homesley 2007
Ifo vs ifo/paclitaxel 91 vs 88 29% vs 45%
p =0.02
3.6 vs5.8
p=0.03
8.4 vs 13.5
p=0.03
GOG 232B Powell 2010
Paclitaxel /carboplatino 46 54% 7.6 14.7
![Page 12: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/12.jpg)
GOG 0261 Statistical Design: intention-to-treat analysis among eligible patients non-inferiority design
![Page 13: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/13.jpg)
![Page 14: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/14.jpg)
![Page 15: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/15.jpg)
GOG 0261: QOL analysis
Presented By Matthew Powell at 2019 ASCO Annual Meeting
![Page 16: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/16.jpg)
Rationale for single agent IO in Endometrial cancer<br />Molecular classification of endometrial cancer - TCGA
Presented By Kimberly Levinson at 2019 ASCO Annual Meeting
![Page 17: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/17.jpg)
Single Agent IO
Presented By Kimberly Levinson at 2019 ASCO Annual Meeting
![Page 18: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/18.jpg)
Study Schema
![Page 19: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/19.jpg)
Baseline characteristics
Presented By Yoland Antill at 2019 ASCO Annual Meeting
![Page 20: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/20.jpg)
![Page 21: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/21.jpg)
CHECKPOINT INHIBITORS
CARCINOMA ENDOMETRIO
- ≤20% ORR CARCINOMA ENDOMETRIO AVANZATO IN PROGRESSIONE
- 15-20% MISMATCH REPAIR DEFICIENCY (dMMR)
IPERMETILAZIONE -MUTAZIONE GERMLINE O SOMATICA
- DURVALUMAB E’ ATTIVO dMMR
- dMMR IN IHC CORRELA CON LA RISPOSTA
![Page 22: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/22.jpg)
Study 111/Keynote 146: Lenvatinib plus pembrolizumab in advanced endometrial cancer: interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Presented By Vicky Makker at 2019 ASCO Annual Meeting
![Page 23: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/23.jpg)
<br />KEYNOTE-775/E7080-G000-309: Randomized, open-label, phase 3 study to evaluate efficacy and safety of lenvatinib and pembrolizumab vs treatment of physician’s choice in
patients with advanced EC in patients with advanced EC- NCT03517449
Presented By Vicky Makker at 2019 ASCO Annual Meeting
![Page 24: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/24.jpg)
È necessaria la chemioterapia nel trattamento
della recidiva del carcinoma ovarico?
![Page 25: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/25.jpg)
ENGOT-OV24 / NSGO-AVANOVA2 trial design
![Page 26: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/26.jpg)
Primary endpoint: PFS in the ITT population
Presented By Mansoor Mirza at 2019 ASCO Annual Meeting
![Page 27: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/27.jpg)
PFS by stratification factors: Chemotherapy-free interval
Presented By Mansoor Mirza at 2019 ASCO Annual Meeting
![Page 28: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/28.jpg)
PFS by stratification factors: HRD status
Presented By Mansoor Mirza at 2019 ASCO Annual Meeting
![Page 29: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/29.jpg)
PFS by BRCA status
Presented By Mansoor Mirza at 2019 ASCO Annual Meeting
![Page 30: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/30.jpg)
Presented By Mansoor Mirza at 2019 ASCO Annual Meeting
![Page 31: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/31.jpg)
![Page 32: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/32.jpg)
Slide 9
Presented By Adriaan Vanderstichele at 2019 ASCO Annual Meeting
![Page 33: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/33.jpg)
Slide 10
Presented By Adriaan Vanderstichele at 2019 ASCO Annual Meeting
![Page 34: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/34.jpg)
Presented By Adriaan Vanderstichele at 2019 ASCO Annual Meeting
![Page 35: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/35.jpg)
Carcinoma della cervice localmente avanzato:
chemioterapia seguita da chirurgia o chemio-radioterapia?
![Page 36: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/36.jpg)
Slide 2
![Page 37: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/37.jpg)
Slide 8
Presented By Gemma Kenter at 2019 ASCO Annual Meeting
![Page 38: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/38.jpg)
Slide 17
Presented By Gemma Kenter at 2019 ASCO Annual Meeting
![Page 39: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/39.jpg)
Slide 19
Presented By Gemma Kenter at 2019 ASCO Annual Meeting
![Page 40: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/40.jpg)
Slide 22
Presented By Gemma Kenter at 2019 ASCO Annual Meeting
![Page 41: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/41.jpg)
WORKING IN PROGRESS: FASE II
ADAVOSERTIB
MIRVETUX/BEVACIZUMAB
PEMBROLIZUMAB/CARBOPLATINO BASSE DOSI
LETROZOLO/RIBOCICLIB
OLAPARIB/CEDIRANIB
![Page 42: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/42.jpg)
Adavosertib
Presented By Joan Walker at 2019 ASCO Annual Meeting
![Page 43: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/43.jpg)
Response Rates Platinum Resistant Ovarian Cancer
![Page 44: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/44.jpg)
Adverse Events
Presented By Joan Walker at 2019 ASCO Annual Meeting
![Page 45: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/45.jpg)
Slide 21
Presented By Elise Kohn at 2019 ASCO Annual Meeting
![Page 46: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/46.jpg)
![Page 47: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/47.jpg)
Slide 14
Presented By Elise Kohn at 2019 ASCO Annual Meeting
23 PAZIENTI VALUTABILI PER RISPOSTA
PR 13% SD 65,2% PD 21.7%
![Page 48: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/48.jpg)
![Page 49: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/49.jpg)
![Page 50: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/50.jpg)
Olaparib/cediranib
![Page 51: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/51.jpg)
Olaparib/cediranib
Presented By Iain McNeish at 2019 ASCO Annual Meeting
![Page 52: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/52.jpg)
EVOLVE - study Design
Presented By Iain McNeish at 2019 ASCO Annual Meeting
![Page 53: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/53.jpg)
EVOLVE – primary objectives
Presented By Iain McNeish at 2019 ASCO Annual Meeting
![Page 54: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/54.jpg)
EVOLVE – putative resistance mechanisms
Presented By Iain McNeish at 2019 ASCO Annual Meeting
![Page 55: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/55.jpg)
TUMORE OVARICO MALIGNO A CELLULE GERMINALI
MOGCT
1-2 % dei tumori ovarici
10-30 anni
Trattamento standard PEB
![Page 56: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/56.jpg)
Abstract 5516: MITO-9 Prospective observational study of non-epithelial ovarian tumors – MOGCT outcomes
Presented By BJ Rimel at 2019 ASCO Annual Meeting
![Page 57: HIGHLIGHTS IN GYNECOLOGICAL CANCER€¦ · Italfarmaco MSD Pharmamar Roche Principal invastigator: ATHENA, FIRST . OBIETTIVO PRIMARIO: FATTIBILITA’ DI 3 REGIMI CHEMIOTERAPICI >](https://reader033.vdocument.in/reader033/viewer/2022060706/6072592230b1bf004e39c96e/html5/thumbnails/57.jpg)
QuickTime™ e undecompressore
sono necessari per visualizzare quest'immagine.
DANIELA SAMBATARO UOC Oncologia Medica
ARNAS GARIBALDI Catania
HIGHLIGHTS IN GYNECOLOGICAL CANCER